루이소체 치매의 개정 진단기준 및 치료의 고찰

• 영문명: New Diagnostic Criteria and Treatment for Dementia with Lewy Bodies
• 발행기관: 대한노인정신의학회
• 저자명: 손보경(Bo Kyung Sohn) 이동우(Dong Woo Lee)
• 간행물 정보: 『노인정신의학』노인정신의학 제24권 제2호, 60~68쪽, 전체 9쪽
• 주제분류: 의약학 > 정신과학
• 파일형태: PDF
• 발행일자: 2020.10.30

영문 초록

Dementia with Lewy bodies (DLB) is the second most common cause of neurodegenerative dementia. The Dementia with Lewy Bodies Consortium has revised DLB consensus diagnostic criteria. We reviewed recent (fourth) clinical diagnosis criteria and treatment options. The revised DLB clinical criteria included clinical features and updated diagnostic biomarkers. Compared with third criteria, they removed suggestive features and reassigned rapid eye movement sleep behavior disorder (RBD) in core clinical features with fluctuating cognition, recurrent visual hallucination, and parkinsonism. They classified biomarkers into two groups, indicative and supportive biomarkers, according to diagnostic specificity and evidence quality. Indicative biomarkers included reduced dopamine transporter uptake in basal ganglia demonstrated by single-photon emission CT or positron emission tomography, low uptake 123Iodine- metaiodobenzylguanidine myocardial scintigraphy, and RBD in polysomnography. In treatment of DLB, cholinesterase inhibitor can improve cognitive function and activities of daily living. Neuroleptics should use with caution due to sensitivity in DLB.

목차

서 론

본 론

결 론

REFERENCES

키워드

Lewy body disease Dementia Diagnosis Biomarkers Therapeutics